SMAD2 and neoplasm: Our finding that Smyca binds Smad3 but not Smad2 to elevate the expression of pro-tumor effectors of Smad not only is consistent with these previous studies but also suggests Smyca as one factor that contributes to the differential effects of Smad2 and Smad3 on tumor progression.